指南与共识炎症性肠病

加拿大胃肠病学会炎症性肠病患者免疫接种临床实践指南(第一部分:活疫苗)

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines.
指南 / 共识 · Gastroenterology · 2021-02-19

该指南由加拿大胃肠病学会制定、美国胃肠病协会认可,基于系统评价与GRADE方法,针对成人及儿童炎症性肠病(IBD)患者活疫苗接种提出推荐。核心结论为:未使用免疫抑制治疗者推荐接种麻腮风及水痘活疫苗,使用免疫抑制治疗者不推荐;对母亲使用生物制剂所生婴儿的活疫苗接种未作推荐。

要点

  • IBD诊断时及定期评估疫苗接种状态,尽早接种适当疫苗。
  • 不应为接种疫苗而延迟急需的免疫抑制治疗。
  • 未用免疫抑制治疗者推荐麻腮风和水痘活疫苗,用药者不推荐。

核心结论

  • 一般推荐未使用免疫抑制治疗的IBD患者接种活疫苗,但不推荐正在使用免疫抑制治疗者接种。
  • 对母亲使用生物制剂所生婴儿的活疫苗接种,因利弊接近平衡且证据不足,未作推荐。

研究设计与样本

  • 加拿大胃肠病学会制定、美国胃肠病协会认可的临床实践指南,采用系统评价与GRADE方法。
  • 系统评价评估IBD患者、其他免疫介导炎症性疾病患者及一般人群中疫苗的效力、效果和安全性。
  • 关键问题经多学科小组迭代开发并投票,采用证据到决策框架制定推荐。

主要发现

  • 制定3条良好实践声明:诊断时及定期审查疫苗接种状态、尽早接种适当疫苗、不延迟急需免疫抑制治疗以接种疫苗。
  • 关于活疫苗使用共4条推荐,涉及麻腮风疫苗和水痘疫苗在成人与儿童IBD患者中的使用。

关键数值与推荐

  • 麻腮风疫苗推荐用于未使用免疫抑制治疗的成人和儿童IBD患者,不推荐用于使用免疫抑制药物者(条件性推荐)。
  • 水痘疫苗推荐用于未使用免疫抑制治疗的儿童IBD患者,不推荐用于使用免疫抑制药物者(条件性推荐)。
  • 成人水痘疫苗条件性推荐用于未使用免疫抑制治疗者,条件性不推荐用于使用免疫抑制治疗者。
  • 强推荐指多数患者应接受推荐方案,条件性推荐指不同患者适合不同选择。

临床怎么用

  • 在IBD诊断时及定期随访中审查疫苗接种状态,并尽早接种适当疫苗。
  • 不应为了接种疫苗而延迟急需的免疫抑制治疗。
  • 对未使用免疫抑制治疗的患者可考虑接种麻腮风和水痘活疫苗,使用免疫抑制治疗者避免接种。
  • 母亲使用生物制剂所生婴儿的活疫苗接种需个体化权衡,因证据不足未作推荐。

局限性

  • 母亲使用生物制剂所生婴儿的活疫苗接种证据不足,无法形成推荐。
  • 需进一步研究评估使用免疫抑制治疗患者接种活疫苗的安全性和效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with inflammatory bowel disease (IBD) may be at increased risk of some vaccine-preventable diseases. The effectiveness and safety of vaccinations may be altered by immunosuppressive therapies or IBD itself. These recommendations developed by the Canadian Association of Gastroenterology and endorsed by the American Gastroenterological Association, aim to provide guidance on immunizations in adult and pediatric patients with IBD. This publication focused on live vaccines. METHODS: Systematic reviews evaluating the efficacy, effectiveness, and safety of vaccines in patients with IBD, other immune-mediated inflammatory diseases, and the general population were performed. Critical outcomes included mortality, vaccine-preventable diseases, and serious adverse events. Immunogenicity was considered a surrogate outcome for vaccine efficacy. Certainty of evidence and strength of recommendations were rated according to the GRADE (Grading of Recommendation Assessment, Development, and Evaluation) approach. Key questions were developed through an iterative process and voted on by a multidisciplinary panel. Recommendations were formulated using the Evidence-to-Decision framework. Strong recommendation means that most patients should receive the recommended course of action, whereas a conditional recommendation means that different choices will be appropriate for different patients. RESULTS: Three good practice statements included reviewing a patient's vaccination status at diagnosis and at regular intervals, giving appropriate vaccinations as soon as possible, and not delaying urgently needed immunosuppressive therapy to provide vaccinations. There are 4 recommendations on the use of live vaccines. Measles, mumps, rubella vaccine is recommended for both adult and pediatric patients with IBD not on immunosuppressive therapy, but not for those using immunosuppressive medications (conditional). Varicella vaccine is recommended for pediatric patients with IBD not on immunosuppressive therapy, but not for those using immunosuppressive medications (conditional). For adults, recommendations are conditionally in favor of varicella vaccine for those not on immunosuppressive therapy, and against for those on therapy. No recommendation was made regarding the use of live vaccines in infants born to mothers using biologics because the desirable and undesirable effects were closely balanced and the evidence was insufficient. CONCLUSIONS: Maintaining appropriate vaccination status in patients with IBD is critical to optimize patient outcomes. In general, live vaccines are recommended in patients not on immunosuppressive therapy, but not for those using immunosuppressive medications. Additional studies are needed to evaluate the safety and efficacy of live vaccines in patients on immunosuppressive therapy.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Benchimol EI, Tse F, Carroll MW, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 1: Live Vaccines. Gastroenterology. 2021. PMID: 33617891. doi:10.1053/j.gastro.2020.12.079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。